Welcome to our succinct summaries of the most recent healthcare news and insights. Keep yourself informed with our easily digestible updates sourced from medical media and news outlets.

Projected Lifetime Cancer Risks From Current Computed Tomography Imaging

  • April 2025
  • JAMA Internal Medicine
  • CT imaging in the U.S. in 2023 was projected to result in approximately 103,000 future radiation-induced cancers, with the highest risks observed in younger patients but the greatest burden borne by adults due to higher utilization. Lung, colon, leukemia, and bladder cancers were the most frequently projected, with breast cancer notably common among women. Abdomen/pelvis and chest CTs contributed the largest share of exposures.
  • These findings underscore the long-term oncologic implications of current CT imaging practices. If utilization and radiation dose trends remain unchanged, CT-related cancers may represent up to 5% of annual cancer incidence, highlighting the importance of imaging appropriateness, dose optimization, and ongoing risk-benefit evaluation in clinical decision-making.
  • Abstract
  • Full text

Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism

  • April 2025
  • New England Journal of Medicine
  • In patients with active cancer and prior venous thromboembolism (VTE) who had completed at least six months of anticoagulation, extended treatment with reduced-dose apixaban (2.5 mg BID) was found to be noninferior to the full dose (5 mg BID) in preventing recurrent VTE over 12 months. The trial was randomized, double-blind, and centrally adjudicated, providing robust evidence for maintenance-phase anticoagulation strategies.
  • Reduced-dose apixaban was associated with a lower rate of clinically relevant bleeding compared to the full dose, suggesting a favorable risk-benefit profile for long-term anticoagulation in this high-risk population. These findings support consideration of dose de-escalation to minimize bleeding risk while maintaining thromboembolic protection in cancer-associated thrombosis.
  • Abstract
  • Full text

Global, regional, and national burden of household air pollution, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

  • April 2025
  • The Lancet
  • Despite global reductions in the use of solid fuels for cooking, household air pollution (HAP) remains a major contributor to global disease burden, with 2.67 billion people still exposed as of 2021. While age-standardized HAP-attributable DALYs declined by nearly 64% since 1990, over 111 million DALYs in 2021 were still linked to conditions such as COPD, ischemic heart disease, stroke, lower respiratory infections, and adverse reproductive outcomes—particularly in sub-Saharan Africa and South Asia.
  • Updated modeling from the Global Burden of Disease Study, incorporating refined exposure estimates by fuel type and advanced exposure–response curves, highlights the persistent health impact of HAP, particularly in low-resource settings. Continued exposure reductions have been offset by population growth, underscoring the urgent need for scalable, region-specific interventions to transition households to clean cooking technologies and reduce the long-term health impact of ambient PM2.5 exposure.
  • Abstract
  • Full text

Optimal dietary patterns for healthy aging

  • March 2025
  • Nature Medicine
  • In a 30-year prospective analysis of over 105,000 participants from the Nurses’ Health Study and Health Professionals Follow-Up Study, greater adherence to high-quality dietary patterns—particularly the Alternative Healthy Eating Index (AHEI)—was significantly associated with increased odds of healthy aging. Healthy aging was defined by survival to at least age 70 without major chronic diseases and with preserved cognitive, physical, and mental function. The strongest associations were observed for diets rich in fruits, vegetables, whole grains, legumes, nuts, unsaturated fats, and low-fat dairy.
  • Conversely, higher consumption of trans fats, sodium, sugar-sweetened beverages, and red or processed meats was negatively associated with healthy aging outcomes. These findings underscore the long-term impact of dietary choices on aging trajectories and support the integration of plant-forward, nutrient-dense eating patterns into preventive health strategies aimed at maintaining function and quality of life in older adults.
  • Abstract
  • Full text

CONSORT 2025 statement: updated guideline for reporting randomised trials

  • April 2025
  • BMJ
  • The CONSORT 2025 update introduces a revised 30-item checklist to enhance the clarity, transparency, and completeness of randomized trial reporting, reflecting methodological advances and stakeholder input since the last update in 2010. Key changes include seven new items, integration of elements from key CONSORT extensions (e.g., harms, non-pharmacologic treatments), and a dedicated section on open science practices.
  • Developed through a rigorous process involving literature review, expert consensus, and a Delphi survey of over 300 international participants, CONSORT 2025 provides a critical framework for authors, reviewers, and editors. The accompanying expanded checklist offers detailed guidance to promote consistency and integrity in trial reporting across diverse clinical research domains.
  • Abstract
  • Full text

Averted lung cancer deaths due to reductions in cigarette smoking in the United States, 1970–2022

  • March 2025
  • CA: A Cancer Journal for Clinicians
  • From 1970 to 2022, an estimated 3.86 million lung cancer deaths were averted in the U.S.—primarily due to declining smoking rates—resulting in over 76 million person-years of life gained. These gains reflect substantial progress in cancer prevention, with an average of nearly 20 years of life preserved per averted death, and a more pronounced impact seen among men and White populations.
  • Averted lung cancer deaths accounted for over half of the overall decline in cancer mortality during this period, underscoring the critical public health impact of tobacco control measures. Despite progress, disparities persist across sex and racial groups, emphasizing the ongoing need for targeted tobacco cessation and prevention efforts to further reduce lung cancer burden.
  • Abstract
  • Full text

Global Consensus Recommendations for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis

  • April 2025
  • Gastroenterology
  • Despite the increasing prevalence and clinical significance of MASLD and MASH, inconsistencies across national and international guidelines have led to confusion and hindered optimal implementation of care. The recent FDA approval of resmetirom for MASH treatment underscores the urgent need for unified clinical guidance to support effective diagnosis, risk stratification, and management.
  • Through a structured Delphi process analyzing 61 guidelines across eight clinical domains, a high-level expert consensus was reached, resulting in harmonized recommendations with >90% agreement across all final statements. These consensus-based algorithms and tables offer a standardized foundation to support evidence-based, coordinated care for patients with MASLD and MASH.
  • Abstract
  • Full text

Effectiveness of Single Versus Multiple Inhaler Triple Therapy on Mortality and Cardiopulmonary Risk Reduction in COPD: The SKOPOS-MAZI Study

  • April 2025
  • The American Journal of Medicine
  • In a real-world comparative effectiveness study of over-40 patients with COPD, initiation of single inhaler triple therapy (BGF: budesonide/glycopyrrolate/formoterol fumarate) was associated with an 18% reduction in all-cause mortality and a 12% reduction in severe cardiopulmonary events compared to multiple inhaler triple therapies (MITTs). These findings were consistent across various analytic models and sensitivity analyses.
  • After adjusting for baseline differences using inverse propensity weighting, BGF demonstrated a more favorable cardiopulmonary risk profile than MITTs. These results support the clinical value of simplifying COPD management with SITTs and highlight BGF as a potentially superior option for reducing adverse outcomes in this high-risk population.
  • Abstract
  • Full text

Thank you for staying updated on the latest healthcare news and insights. Don't miss out on important information - sign up for alerts and stay informed on the latest published guidelines and articles.

Copyright © 2025 Guideline Central, All rights reserved.